No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EVOK Evoke Pharma
- 0.4580
- +0.0220+5.05%
Close Apr 26 16:00 ET
- 0.4800
- +0.0220+4.80%
Post 16:40 ET
3.88MMarket Cap-196P/E (TTM)
0.4800High0.4370Low8.75KVolume0.4610Open0.4360Pre Close4.12KTurnover0.20%Turnover RatioLossP/E (Static)8.48MShares2.399952wk High-1.51P/B2.01MFloat Cap0.415952wk Low--Dividend TTM4.38MShs Float171.0000Historical High--Div YieldTTM9.86%Amplitude0.4159Historical Low0.4700Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
Evoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer
By Denny Jacob Evoke Pharma tapped Matthew D'Onofrio to succeed David Gonyer as chief executive, effective March 31. D'Onofrio, who currently serves as president and chief operating officer, will as
Evoke Pharma: Gonyer's Departure Is for Personal Reasons >EVOK
Evoke Pharma: Gonyer's Departure Is for Personal Reasons >EVOK
Evoke Pharma : Matthew D'Onofrio Will Be Succeeding David Gonyer as CEO as of March 31 >EVOK
Evoke Pharma : Matthew D'Onofrio Will Be Succeeding David Gonyer as CEO as of March 31 >EVOK
Press Release: Evoke Pharma Announces Senior Leadership Transition With Promotion of Matthew J. D'Onofrio to Chief Executive Officer
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASD
Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?
Comments
New 13G
$Evoke Pharma(EVOK.US$ Evoke Pharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Altium Capital Management, LP EIN:(9.7%),Altium Growth Fund, LP EIN:(9.7%), etc.
SEC announcement· 1 min ago
SEC announcement· 1 min ago
1
#2023 Recap:My trading story
2023 was a year full of tears and fun. Tear because of the leak of knowledge and trade with emotional. Fun because of earning a bit at the end of 2023. Thanks to Moomoo, provided an endless course, technique to equip me with correct trading direction without any more emotional.
My biggest lost is Evoke Pharma due to me as a fresh one trading with emotional.
Thanks for QQQ, I gained a bit to recover my loss.
Look ahead more gaining in 2024.
2023 was a year full of tears and fun. Tear because of the leak of knowledge and trade with emotional. Fun because of earning a bit at the end of 2023. Thanks to Moomoo, provided an endless course, technique to equip me with correct trading direction without any more emotional.
My biggest lost is Evoke Pharma due to me as a fresh one trading with emotional.
Thanks for QQQ, I gained a bit to recover my loss.
Look ahead more gaining in 2024.
5
Update
$Evoke Pharma(EVOK.US$ Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
3 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
3 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
1
Update
$Evoke Pharma(EVOK.US$ United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
2 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
2 MINUTES AGO, 8:30 AM EST
VIA GLOBENEWSWIRE
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg